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Evaluation of a Program to Improve Diabetes Care 
Through Intensified Care Management Activities and 
Diabetes Medication Copayment Reduction
Stephen J. Kogut, PhD, MBA; Scott Johnson, PharmD, MS;  
Tara Higgins, BS Pharm, CDOE; and Brian J. Quilliam, PhD
ABSTRACT
BACKGROUND: Medication copayment reduction can be integrated with dis-
ease management programs to incentivize patient engagement in chronic 
care management. While disease management programs in diabetes have 
been evaluated across a range of settings and designs, less is known 
regarding the effectiveness of copayment reduction as a component of 
disease management. 
OBJECTIVE: To evaluate the short-term results of a diabetes-focused dis-
ease management program that included copayment reduction, care coor-
dination, and patient goal setting, focusing on rates of evidence-based care 
processes and all-cause pharmacy and health care costs. 
METHODS: Blue Cross & Blue Shield of Rhode Island offered large employer 
groups the opportunity to participate in a diabetes disease management 
initiative that featured reduced copayments (from $7/$25/$40 for generic, 
tier 2, and tier 3 drugs, respectively, to $0 for generic and $0-$2 for brand 
drugs) for diabetes-related medications. In return for the copayment reduc-
tion, participants agreed to the following: (a) participate in care coordina-
tion with a case manager, (b) have an annual physical examination, (c) have 
a hemoglobin A1c blood test at least twice annually, and (d) have a low-
density lipoprotein cholesterol (LDL-C) test at least once annually. Patients 
received personalized support provided by a registered nurse and dieti-
cian, disease-related education provided by nurses, and intensified case 
management services, including working with a health coach to establish 
healthy behavioral change goals. All study subjects were aged 18 years or 
older and had at least 1 ICD-9-CM code for diabetes and at least 1 claim 
for an antidiabetic drug during a 12-month measurement period, which was 
each subject’s most recent 12-month period of continuous enrollment from 
January 1, 2008, through May 31, 2010. Administrative claims data were 
used to determine the percentage of intervention (participating) and nonin-
tervention (nonparticipating) subjects from among all of the plan’s employ-
er groups who received at least once-yearly monitoring of A1c, high-density 
lipoprotein cholesterol (HDL-C), and LDL-C; medical attention (or drug 
therapy) for nephropathy; and an eye examination. We conducted multivari-
ate logistic regression analyses to assess the effect of the intervention and 
other patient characteristics and comorbidities on rates of performance of 
these care processes, aggregating the 5 processes of care into an “all or 
none” single composite outcome. We also developed a propensity score-
weighted model to attempt to adjust for differences between the interven-
tion and nonintervention groups resulting from the nonrandomized study 
design. Additionally, we quantified average plan payments to providers less 
RESEARCH
patient copayments (i.e., net plan cost) per patient per year (PPPY) for the 
12-month follow-up period and compared these costs for the intervention 
versus nonintervention groups. 
RESULTS: The study sample consisted of 9,698 patients with diabetes; 649 
(6.7%) of whom participated in the intervention. 9,049 (93.3%) patients 
were identified by the insurer as patients with diabetes receiving usual 
care. Patients in the intervention and nonintervention groups were similarly 
likely to have all 5 recommended processes of care performed (40.1% vs. 
38.9%, respectively, P = 0.543). Younger patients received all 5 recom-
mended care processes less frequently than older patients (30.5%, 38.0%, 
and 47.0% for ages 18-48 years, 49-59 years, and 60 years or older, 
respectively, P < 0.001); in adjusted analyses, patients aged 60 years or 
older were approximately twice as likely to receive all 5 care processes 
compared with patients aged 18-48 years (odds ratio [OR] = 1.97, 95% 
CI = 1.75-2.21). Users of oral antidiabetic monotherapy were least likely to 
have these processes of care performed compared with users of multiple 
oral therapies (OR = 1.23, 95% CI = 1.11-1.36) and insulin (OR = 1.59, 95% 
CI = 1.41-1.78). PPPY prescription drug costs incurred by the plan were 
greater for intervention than comparison patients (means [SDs] of $3,139 
[$3,426 ] vs. $2,854 [$3,938], respectively, P < 0.001); and the generic-
dispensing ratio was slightly lower (means [SDs] of 62.1% [22.4%] and 
65.4% [23.0%], respectively, P < 0.001). There were no significant dif-
ferences between the intervention and comparison groups in mean [SD] 
PPPY all-cause medical care costs ($7,475 [$17,601] vs. $8,577 [$22,972], 
respectively, P = 0.213) or total all-cause costs ($10,613 [$18,590] vs. 
$11,431 [$24,060], P = 0.666). 
CONCLUSIONS: Patients participating in this incentive program featuring 
diabetes medication copayment reduction and disease management com-
ponents did not receive recommended care any more or less frequently 
than other enrolled members with diabetes. Younger patients and those 
utilizing oral antidiabetic monotherapy as their drug regimens were less 
likely to have the recommended processes of care performed. While pre-
scription drug expenditures incurred by the plan were greater for interven-
tion patients, between-group differences in total costs for medications and 
all-cause medical care were not statistically significant. Further follow-up 
is required to determine the success of this program over the longer term 
in promoting quality of care and achieving cost reductions and improved 
health outcomes. 
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Diabetes mellitus is a major burden on the U.S. health care system. Estimates from the U.S. Centers for Disease Control indicate that approximately 26 million 
people in the United States are living with diabetes, including 
7 million Americans who are undiagnosed, while nearly 2 mil-
lion adults were newly diagnosed with diabetes during 2010.1 It 
is estimated that 1 in 3 people in the United States will develop 
diabetes during their lifetime.2 Diabetes is the sixth leading 
cause of death in the United States, contributing to approxi-
mately 225,000 deaths yearly.3 In 2002, diabetes contributed to 
16.9 million days of hospitalization and 62.6 million physician 
office visits, and total average health care expenditures were 
$13,243 for every person with diabetes compared with $5,642 
for every person without diabetes, controlling for age and 
other demographic characteristics.4 These figures underscore 
why the health care system continues to devise and implement 
interventions to manage the disease and reduce diabetes-
related complications and associated costs.
As a result of the high prevalence5 and cost burden6 associ-
ated with diabetes and its complications, managed care orga-
nizations are directing significant resources towards ensuring 
that evidence-based care is routinely delivered to promote risk 
reduction and avert untoward health outcomes. Quality of 
care recommendations for diabetes supported by the American 
Diabetes Association include the routine measurement of 
glycosylated hemoglobin (A1c), blood lipids and renal func-
tion, and routine diabetic retinal examinations for preventing 
disease complications.7 Poor glycemic control and dyslipidemia 
are significant risk factors for coronary artery disease (CAD) 
•	Although	 diabetes	 management	 has	 improved	 during	 the	 past	
decade, there is opportunity for improvement. The National 
Committee on Quality Assurance (NCQA) Healthcare 
Effectiveness Data and Information Set (2009) indicated that 
approximately 89% of commercially insured patients with dia-
betes had hemoglobin A1c measured at least once yearly, while 
rates for low-density lipoprotein cholesterol (LDL-C) screening 
and monitoring for nephropathy were 85% and 82%, respec-
tively. Lower rates were reported for the performance of diabetic 
eye examinations (57%). The 2010 National Healthcare Quality 
Report found that in 2007, 88% of patients with diabetes had A1c 
measured, and 61% received eye examinations. 
•	The	Medicare	Health	Support	Pilot	Program	(2011),	which	ran-
domized approximately 240,000 Medicare beneficiaries with 
diabetes or heart failure to either standard care or a disease 
management intervention employing remote call centers staffed 
by nurses, found no significant between-group differences in 
hospital admissions or overall costs of care. 
•	A	cluster-randomized	trial	by	Sönnichsen	et	al.	(2010)	evaluated	
a disease management intervention comprising interdisciplinary 
care, face-to-face physician and patient education, standardized 
medication documentation, and shared physician-patient goal 
setting. Compared with 840 study patients receiving usual care, 
the 649 intervention patients more frequently had recommended 
care performed (e.g., eye and foot examinations and A1c measure-
ment) and experienced reductions in body mass index and blood 
cholesterol. However, statistical analyses revealed no sustained 
between-group differences in A1c reduction over time. 
•	Less	 is	 known	about	 the	outcomes	of	 copayment	 reductions	 in	
disease management programs. Gibson et al. (2011) described 
the outcomes of copayment reduction for diabetes medications, 
separately and when coupled with a disease management pro-
gram. Among disease management participants, but not among 
nonparticipants, drug copayment reductions were associated 
with higher rates of completion of A1c, lipid testing, and urinaly-
sis, and results were sustained over a 3-year follow-up period. 
In a study of an initiative implemented by one large employer, 
Chernew et al. (2008) found that copayment reductions from 
$5/$25/$45 to $0/$12.50/$22.50 for generic, tier 2, and tier 3 
medications, respectively, were associated with a 4.02 percentage 
point increase in medication possession ratio (P < 0.001). 
What is already known about this subject
•	Patients	volunteering	to	participate	in	a	diabetes-focused	disease	
management and copayment incentive program had generally 
high rates of annual performance of 4 important elements of 
diabetes care that were similar to those of the plan’s patients with 
diabetes who did not participate in the program (high-density 
lipoprotein cholesterol test: 85.7% vs. 89.7%, P = 0.001; LDL-C 
What this study adds
test: 86.7% vs. 89.8%, P = 0.014; A1c test: 92.3% vs. 94.1%, 
P = 0.064; medical attention for nephropathy: 83.8% vs. 83.3%, 
P = 0.726, respectively). Rates were lower overall for eye exami-
nations, yet similar among intervention versus nonintervention 
patients (51.2% vs. 48.0%, P = 0.114). 
•	The	average	12-month	per	member	all-cause	plan	cost	for	medi-
cations and medical care among intervention patients was similar 
to cost for members with diabetes who did not participate in the 
program ($10,613 vs. $11,430, respectively, P = 0.666). Average 
all-cause medication cost was higher for intervention than com-
parison group patients ($3,139 vs. $2,854, respectively, P < 0.001) 
and the average generic-dispensing ratio was lower (62.1% vs. 
65.4%, respectively, P < 0.001).
•	The	 odds	 of	 receiving	 all	 5	 recommended	 care	 processes	were	
twice as high for patients aged 60 years or older compared with 
patients aged 18 to 48 years (odds ratio [OR] = 1.97, 95% CI = 1.75-
2.21). Compared with users of oral monotherapy, odds were 
23% higher for users of multiple oral therapies (OR = 1.23, 95% 
CI = 1.11-1.36) and 59% higher for insulin users (OR = 1.59, 95% 
CI = 1.41-1.78). 
What this study adds (continued)
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in patients with diabetes. For example, using data from the 
United Kingdom Prospective Diabetes Study to assess risk fac-
tors for CAD, Turner et al. (1998) reported a hazard ratio (HR) 
of 2.26 for low-density lipoprotein cholesterol (LDL-C; 95% 
confidence interval [CI] = 1.70-3.00); HR = 1.52 for A1c (95% 
CI = 1.15-2.01); and HR = 0.55 for high-density lipoprotein cho-
lesterol (HDL-C; 95% CI = 0.41-0.73), comparing patients cate-
gorized within the upper-third versus lowest-third levels.8 The 
prevention of nephropathy and retinopathy is an additionally 
important area of focus. According to data from the National 
Health and Nutrition Examination Survey (NHANES IV), 
approximately 40% of patients with type 2 diabetes have some 
degree of chronic kidney disease, findings that underscore 
the importance of early detection and intervention.9 Zhang 
et al. (2010) determined the prevalence of retinopathy among 
NHANES IV participants with diabetes receiving a medical 
examination, finding that 4.4% had retinopathy classified as 
being a threat to vision.10 
Results from the 2009 National Committee on Quality 
Assurance (NCQA) Healthcare Effectiveness Data and 
Information Set (HEDIS) reveal a generally high level of per-
formance of diabetes-related quality of care processes among 
patients enrolled in commercial plans: approximately 89% of 
patients with diabetes had their A1c measured at least once 
yearly, while rates for LDL-C screening and monitoring for 
nephropathy were 85% and 82%, respectively.11 Lower rates 
were reported for the performance of diabetic eye examinations 
(57%). These results are similar to the findings reported in the 
2010 National Healthcare Quality Report, which revealed that 
88% of patients with diabetes had their A1c measured in 2007, 
while eye examinations were received by 61% of patients.12 
These results also indicate opportunity for improving these 
core measures of routine diabetes care. 
Disease management approaches in diabetes have included 
components such as enhanced patient education, improved 
care coordination, increased involvement of pharmacists, and 
the use of remote call centers for patient support. The Medicare 
Health Support (MHS) Pilot Program, which is the largest eval-
uation of disease management delivered to older patients with 
diabetes published to date, found that disease management 
programs employing remote call centers staffed by nurses were 
ineffective in decreasing hospital admissions or reducing over-
all costs of care.13 In the MHS, more than 240,000 patients with 
diabetes or heart failure were randomized to either the disease 
management intervention or standard care. Improvements 
were noted for only 14 of 40 of the processes of care measured, 
with only small percentage point changes observed. 
A	cluster-randomized	 trial	conducted	by	Sönnichsen	et	al.	
(2010) evaluated a disease management intervention compris-
ing interdisciplinary care, face-to-face physician and patient 
education, standardized medication documentation, and 
shared physician-patient goal setting delivered to 649 Austrian 
patients with diabetes.14 Compared with the 840 study patients 
receiving usual care, intervention patients more frequently had 
recommended care performed (e.g., eye and foot examinations 
and A1c measurement) and experienced reductions in body 
mass index and blood cholesterol. A small improvement (0.13 
percentage point) was observed in reduction of A1c among 
intervention patients, yet the difference in A1c reduction 
between intervention and control patients was not sustained 
after statistical adjustment for cluster effects and status at 
baseline.14 A randomized trial by Hogg et al. (2009) found that 
Anticipatory and Preventive Team Care (APTCare) involving 
nurse practitioners and pharmacists delivered to 120 patients 
yielded improvements in guideline-based processes of care 
across several conditions including diabetes.15 However, the 
improvements in the diabetes-specific measures were not sta-
tistically significant nor were significant differences observed 
in rates of hospitalization or patient quality of life between the 
intervention and usual care groups. 
Disease management programs including diabetes medi-
cation copayment reduction or waiver have been evaluated 
as a means of improving diabetes care and reducing cost. 
Noteworthy models include the Asheville Diabetes Care Project 
(Asheville Project)16 and the subsequent Diabetes Ten City 
Challenge.17 While the primary focus of the Asheville Project 
was to apply pharmaceutical care services specific to diabetes 
management, the initiative also offered participants copayment 
waivers for diabetes medications and supplies. The evaluation 
measures employed in the Asheville Project focused upon the 
achievement of therapeutic goals; patients who did not have 
A1c and lipid measurements performed were considered lost 
to follow-up. Participants in the Asheville Project reported 
that the medication copayment waiver was a highly important 
factor in agreeing to participate in the program.18 Results of 
the Diabetes Ten City Challenge included increases in rates 
of performance of several diabetes-related processes of care, 
including eye examinations (from 57% at baseline to 81%), 
yearly A1c testing (54% to 97%), and yearly lipid profile tests 
(51% to 92%), while average total health care costs per person 
were reduced by $1,080 for the 1-year study period.17 
However, the improvements in diabetes care and outcomes 
reported in these 2 studies should be interpreted cautiously in 
consideration of the nonexperimental designs employed and 
the health status of study participants at baseline. Patients 
participating in the Asheville Project were not randomized to 
the intervention, and a majority (more than 61%) of patients 
entered the study with poorly controlled diabetes (A1c level 
exceeding 7%). In the Diabetes Ten City Challenge, patient 
enrollment was voluntary, and the study employed a pre-post 
design without a control group comparison. While improve-
ments in rates of performance of diabetes-related care pro-
cesses were substantial, it is uncertain if these improvements 
differed from usual care patterns among the employers’ non-
participating employees with diabetes. 
Evaluation of a Program to Improve Diabetes Care Through Intensified Care  
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In the years following these 2 important studies, the value 
of medication therapies has been a growing consideration in 
formulary designs,19,20 and the results of comparative effective-
ness research may yet support copayment variation based on 
expected value for a particular patient’s clinical circumstance.21 
Yet, there has been a paucity of research examining the effect 
of copayment waiver or reduction on patient health outcomes, 
quality of care, and cost. 
Gibson et al. (2011) described the outcomes of a value-based 
insurance design including copayment reduction for diabetes 
medications, as evaluated separately and when coupled with a 
disease management program.22 This was a voluntary program 
offered by one large employer to all of its employees with dia-
betes. These researchers found that the intervention including 
both the pharmacy copayment reduction and disease manage-
ment components yielded higher rates of completion of A1c, 
lipid testing, and urinalysis, compared with disease manage-
ment alone. The results were sustained over a 3-year follow-up 
period. Chernew et al. (2008)23 and Chang et al. (2010)24 also 
reported improvements in diabetes medication adherence asso-
ciated with copayment reduction or waiver, although neither of 
these studies employed a randomized design, and in the study 
by Chang et al., copayment reduction was not incorporated 
within a defined disease management program.
In 2008, Blue Cross & Blue Shield of Rhode Island (RI) ini-
tiated an employer-based voluntary pilot program to improve 
diabetes-related care. Our aim was to describe the association 
of the program with the quality of care received, focusing 
upon the performance of 5 diabetes-related processes of care: 
annual LDL-C, HDL-C, and A1c testing; medical attention for 
nephropathy; and eye examinations. We sought to determine if 
patients participating in the program more frequently received 
these processes of care during a 12-month period compared 
with all other Blue Cross & Blue Shield of RI members with 
diabetes who were not enrolled in the program. Between these 
groups, we also compared the average per-member costs asso-
ciated with the utilization of prescription drugs and medical 
services. 
■■  Methods
Design and Intervention
We employed a retrospective, cross-sectional design, using 
electronic claims data to describe patients’ health service 
utilization and associated cost during a 12-month time frame 
between January 1, 2008, and May 31, 2010. All patients had 
at least 12 continuous months of enrollment and were at least 
18 years of age. The data sources used in this analysis included 
medical, pharmacy, and enrollment data files, providing demo-
graphic information, medical diagnoses, health care proce-
dures, medication dispensings, and hospital discharge records. 
These data included associated costs where applicable. 
The main elements of the program included disease 
education, counseling, and close oversight provided by 
assigned nurse case managers and copayment reductions for 
diabetes-related medications. Specifically, medication copay-
ments for intervention members were reduced to either $2.00 
for brand name medications and $0 (zero) for generic medica-
tions, or to a $0 copayment for both brand and generic anti-
diabetic medications, depending upon the account. The 3-tier 
pharmacy benefit design for members not participating in the 
program remained as $7/$25/$40 for generic, tier 2, and tier 3 
medications, respectively. The program required that partici-
pants agree to the following: (a) participate in care coordination 
with their case managers, (b) have an annual physical exam, 
(c) have an A1c blood test at least twice a year, and (d) have 
an LDL-C test performed at least once per year. Additionally, 
patients received personalized support provided by a registered 
nurse and dietician, which included working to achieve health-
related goals. Patients also received disease-related education 
provided by nurses and intensified case management services, 
including working with a health coach to establish healthy 
behavioral change goals. Members also completed a contract 
that pledged their agreement to remain engaged in care and to 
receive recommended tests and health exams. Participants were 
informed that the copayment reduction would be rescinded if 
they did not receive recommended tests and participate in 
care coordination. Patients not participating in the program 
received usual care, which included the plan’s usual disease 
management components such as the provision of educational 
materials and case management following a hospital visit, but 
without personalized goal setting or copayment reductions. 
The diabetes care management activities and diabetes medi-
cation copayment reduction program (i.e., the “intervention”) 
was offered to the plan’s larger employer groups with 1,000 
or more employees. Five of these groups agreed to participate. 
Patient recruitment was performed by Blue Cross & Blue Shield 
of RI, which had sole responsibility for identifying members 
with diabetes in the participating employer groups; invitations 
to participate in the program were mailed by the health plan 
to these patients’ homes. The mailings were followed by a tele-
phone voice reminder message sent 2 weeks later.
The intervention group for the study comprised those mem-
bers who were offered the program and agreed to participate 
through May 31, 2010. For these patients, the study time frame 
consisted of the most recent 12 months of participation in the 
program. The comparison group comprised all other mem-
bers identified by the plan as having diabetes during the time 
frame, including those members from both the large employer 
groups from which the intervention patients were recruited 
and from among all of the plan’s other groups. For the compari-
son cohort, the most recent 12 months of continuous enroll-
ment comprised the study time frame. All patients in both 
groups received a dispensing for either an oral or injectable 
medication for diabetes during the 12-month study time 
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frame and had a diagnosis of diabetes documented during this 
12-month period. We excluded patients who had a primary or 
secondary diagnosis of polycystic ovary syndrome, for which 
metformin may be prescribed. The flowchart in Figure 1 pres-
ents an overview of the study inclusion criteria and sequence. 
Study Outcomes and Statistical Analyses
Our main objectives were to compare (a) rates of performance 
of recommended diabetes-related care processes between 
the intervention and nonintervention groups and (b) all-
cause pharmacy and medical care costs between groups. We 
determined the percentages of patients who received at least 
once-yearly monitoring of A1c, HDL-C, LDL-C, and medical 
attention for nephropathy, which included evidence of renal 
function monitoring, a diagnosis of nephropathy, or use of 
an angiotensin-converting enzyme inhibitor or angiotensin II 
receptor blocker (at least 1 pharmacy claim during the mea-
surement period). We also determined if patients received a 
dilated eye exam during this time span. 
We created an “all or none” single composite outcome 
comprising all these aspects of recommended care. Our mea-
surement specifications were based on the 2009 HEDIS diag-
nosis and procedure code listings,25 with the exception of eye 
examinations; due to our 12-month measurement time frame 
we were unable give credit for negative retinal exam results 
obtained in the prior year, as the HEDIS methodology allows. 
Annual HDL-C monitoring is not included in the HEDIS 
comprehensive diabetes care measure set. Our measure was 
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Must be aged 18 years or 
older (exclude 12)
785
Must be aged 18 years or 
older (exclude 172)
18,320
FIGURE 1 Study Inclusion and Exclusion Criteria
Insurer data extraction: Intervention participants and other members having diabetes
N = 21,153
20,310 nonintervention patientsa843 agreed to participate in the intervention
Continuous enrollment 
at least 12 months between 
January 1, 2008, and  
May 31, 2010 (exclude 46)
797
Continuous enrollment 
at least 12 months between 
January 1, 2008, and  
May 31, 2010 (exclude 1,818)
18,492
Diabetes diagnosis verified 
by ICD-9-CM code and Rx  
use (exclude 136)b
649
Diabetes diagnosis verified 
by ICD-9-CM code and Rx  
use (exclude 9,245)b
9,075
No diagnosis of polycystic 
ovary syndrome (exclude 0)
649
No diagnosis of polycystic 
ovary syndrome (exclude 26)
9,049
aNonintervention patients include those who were offered the intervention program through their employers and patients identified as having diabetes by other employer 
groups that did not offer the intervention.
bDiabetes diagnosis verified by presence of at least 1 defining ICD-9-CM code and at least 1 medication for diabetes dispensed during the 12-month measurement period 
(Appendix).
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; Rx = prescription drug. 
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enrolled by this commercial insurer were middle-aged, non-
elderly working adults and their family members. We cre-
ated age categories that roughly approximated tertiles of the 
distribution, while also maintaining at least a 10-year range 
for the middle strata. Medication burden was determined 
according to the number of unique medications utilized dur-
ing the 12-month study time period, identified via National 
Drug Code (NDC) numbers. This variable represented the sum 
of unique medications utilized during the 12-month study 
period, counting each chemical entity only once, regardless 
of the number of dispensings or the dosage form or strength. 
The type of diabetes medication regimen used during the 12- 
month period was classified as follows: (a) oral monotherapy 
without insulin use; (b) multiple oral therapy without insulin 
use; or (c) any insulin use, with or without concomitant oral 
medication use, also identified using product NDC numbers. 
We also identified the following comorbidities via relevant 
ICD-9-CM codes (appearing at least once during the 12-month 
time frame): asthma, chronic obstructive pulmonary disease 
(COPD), CAD, heart failure, and a mental health condition, 
which included the diagnoses of depression, bipolar disorder, 
and schizophrenia. 
Rates of performance were determined for each of the 
diabetes-related processes of care and for the aggregated com-
posite measure, and these rates were stratified by group status 
and according to the covariates identified above. Pearson chi-
square tests were applied to determine the statistical signifi-
cance of differences in these rates and also to assess differences 
in patient characteristics and the presence of comorbidities 
between the intervention and nonintervention groups. 
A multivariate logistic model was developed to determine 
the effect of the intervention on the outcome of the “all or 
none” measure, defined as having all of the measured processes 
of care performed during the 12-month period. The model 
was created using a manual backward stepwise process. The 
log-likelihood test was used to assess the multivariate model 
at each step, removing least statistically significant covariates 
with each iteration and evaluating differences between full and 
reduced models for statistical significance (P < 0.05). Gender 
and age remained in the model throughout. The Hosmer-
Lemeshow goodness-of-fit test was used to assess the calibra-
tion of the final model. The measure of effect was presented as 
an odds ratio (OR) with corresponding 95% CIs. 
To mitigate bias resulting from the nonrandomized design, 
an inverse propensity score-weighted model was also utilized 
to adjust for the likelihood of intervention group inclusion. A 
2-stage propensity score approach was applied as described by 
D’Agostino (1998),26 which attempted to account for differences 
in diabetes severity and comorbidities between groups, recog-
nizing that volunteers for the diabetes management program 
may have differed in health status from the plan members with 
diabetes who did not participate in the intervention. The first 
calculated using the Current Procedural Terminology (CPT) 
codes for lipid panel and HDL-C testing as acceptable numera-
tor qualifiers. The Appendix presents a listing of International 
Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) and CPT codes used in identifying diagnoses and 
processes of care. 
In addition to comparing rates of these processes of care 
between groups, the intervention and nonintervention groups 
were compared according to age, gender, type of diabetes 
medication used, and comorbidities. Most of the patients 
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Variable
Intervention 
(n = 649)
Nonintervention 
(n = 9,049) P Valuea
Age, years
Mean [SD] age  53.4 [10.72]  54.2 [9.68] < 0.001
 % (n)  % (n)
18 to 48  27.0 (175)  24.8 (2,243) 0.235
49 to 59  43.5 (282)  43.7 (3,957) 0.922
60 or older  29.6 (192)  31.5 (2,849) 0.335
Gender
Male  61.3 (398)  60.7 (5,496) 0.798
Female  38.7 (251)  39.3 (3,553) 0.798
Diabetes medication useb
Oral monotherapy  
(no insulin)
 25.4 (165)  30.0 (2,713) 0.016
Multiple oral therapy 
(no insulin)
 43.6 (283)  44.3 (4,005) 0.770
Any insulin  31.0 (201)  25.8 (2,331) 0.004
Comorbidityc
Asthma  5.5 (36)  7.5 (681) 0.074
COPD  1.1 (7)  2.7 (244) 0.017
CAD  11.9 (77)  16.5 (1,491) 0.002
CHF  4.0 (26)  4.3 (392) 0.774
Mental health diagnosis  8.9 (58)  10.0 (908) 0.408
Number of unique medications utilized during  
the 12-month follow-up measurement periodd
Mean [SD] number  12.2 [7.5]  12.9 [7.6] 0.032
 % (n)  % (n)
0-5  13.7 (89)  12.9 (1,165) 0.579
6-10  35.7 (232)  31.3 (2,833) 0.021
11-20  37.6 (244)  42.1 (3,812) 0.027
21 or more  12.9 (84)  13.7 (1,239) 0.632
aP values determined from Pearson chi-square tests for all categorical comparisons 
and t-tests for independent samples for number of unique medications used and age. 
bMeasured during the 12-month follow-up period.
cDefined as at least 1 relevant confirming diagnosis or procedure code (Appendix) 
during the 12-month follow-up measurement period.
dUnique chemical entity regardless of dosage form or strength.
CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic 
obstructive pulmonary disease; SD = standard deviation.
TABLE 1 Selected Characteristics of Patients 
Participating in the Diabetes 
Incentive Program and Patients 
in the Comparison Group 
(Intervention vs. Nonintervention)
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■■  Results
The insurer identified 21,153 patients with diabetes, 843 of 
whom agreed to participate in the diabetes incentive program; 
20,310 were members identified as having diabetes using algo-
rithms employed by the plan but did not participate in the pro-
gram. Approximately 5.5% of intervention patients and 9.0% of 
nonintervention patients were excluded after application of the 
continuous enrollment criterion. Among those enrolled for at 
least 12 months, 12 intervention patients and 172 noninterven-
tion patients were less than 18 years of age and were excluded. 
We required that patients had at least 1 diagnosis of diabetes 
and at least 1 dispensing of an antidiabetic medication during 
the 12-month period. This criterion resulted in the additional 
exclusion of 136 intervention and 9,245 nonintervention 
patients. After excluding 26 patients from the nonintervention 
group with a diagnosis of polycystic ovary disease, the final 
study sample consisted of 9,698 patients with diabetes, 649 
of (6.7%) of whom were participants in the intervention. No 
intervention patients withdrew from the program during the 
study time frame.
The mean (standard deviation [SD]) ages of patients in the 
intervention and nonintervention groups were similar (53 
[10.7] vs. 54 [9.7] years, respectively), as were the percentages 
stage of this approach aims to predict treatment group (i.e., 
intervention vs. nonintervention status) according to available 
covariates. Variables assessed for incorporation into the pro-
pensity score included the type of diabetes medication utilized, 
the comorbidities identified above, and the number of unique 
medications utilized during the study time frame. Gender and 
age remained in the model throughout, while other variables 
were included if they were significant (P < 0.05) in building a 
fitted multiple logistic regression model having an outcome 
variable representing intervention group status. A correlation 
matrix was used to identify the presence of multicollinearity, 
and potential interactions between variables were explored. 
In the second stage, the inverse propensity-score weight was 
incorporated in a model predicting the diabetes processes of 
care composite measure and including intervention group sta-
tus as a weight-adjusted predictor. 
Additionally, we calculated the 12-month costs of all-cause 
medical care, pharmacy, and total health expenditures and 
compared these costs for the intervention versus noninterven-
tion groups. The Wilcoxon rank-sum (Mann-Whitney U) test 
was used to evaluate differences between cost values. For all 
analyses, we assumed an a priori significance level of P < 0.05 
(2-sided). Data analyses were performed using SAS version 9.2 
(SAS Institute Inc., Cary, NC).
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HDL-C Test
 % (n)
LDL-C Test
 % (n)
A1c Test
 % (n)
Medical Attention 
for Nephropathyb
 % (n)
Eye Exam
 % (n)
All Performed
 % (n)
Group
Intervention (n = 649)  85.7 (556)  86.7 (563)  92.3 (599)  83.8 (544)  51.2 (332)  40.1 (260)
Usual care (n = 9,049)  89.7 (8,120)  89.8 (8,125)  94.1 (8,514)  83.3 (7,537)  48.0 (4,339)  38.9 (3,516)
P = 0.001 P = 0.014 P = 0.064 P = 0.726 P = 0.114 P = 0.543
Age, years
18-48 (n = 2,418)  85.2 (2,061)  85.2 (2,060)  91.9 (2,223)  77.3 (1,868)  41.1 (995)  30.5 (738)
49-59 (n = 4,239)  90.8 (3,849)  91.1 (3,860)  94.6 (4,010)  83.7 (3,549)  46.8 (1,982)  38.0 (1,609)
60 and older (n = 3,041)  91.0 (2,766)  91.0 (2,768)  94.7 (2,880)  87.6 (2,664)  55.7 (1,694)  47.0 (1,429)
P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001
Gender
Male (n = 5,894)  89.9 (5,301)  90.1 (5,310)  94.0 (5,541)  83.6 (4,929)  46.7 (2,751)  38.0 (2,240)
Female (n = 3,804)  88.7 (3,375)  88.8 (3,378)  93.9 (3,572)  82.9 (3,152)  50.5 (1,920)  40.4 (1,536)
P = 0.057 P = 0.042 P = 0.825 P = 0.322 P< 0.001 P = 0.019
Diabetes medication use
Oral monotherapy 
(n = 2,878)
 88.4 (2,543)  88.3 (2,541)  91.9 (2,644)  76.3 (2,195)  44.3 (1,274)  32.5 (936)
Multiple oral therapy 
(n = 4,288) 
 91.4 (3,920)  91.6 (3,927)  95.2 (4,081)  85.3 (3,657)  48.1 (2,063)  39.7 (1,703)
Any insulin (n = 2,532)  87.8 (2,222)  87.7 (2,220)  94.3 (2,388)  88.0 (2,229)  52.7 (1,334)  44.9 (1,137)
P < 0.001 P < 0.001 P < 0.001 P< 0.001 P < 0.001 P < 0.001
aBetween-group differences comparing intervention versus comparison group patients were assessed using Pearson chi-square tests.
bMedical attention for nephropathy includes use of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker drug or documentation of a range of  
procedures that indicate provider attention to renal function.
A1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL-C= low-density lipoprotein cholesterol.
TABLE 2 Frequency and Percentage of Patients with Diabetes Receiving 
Recommended Care by Group Status and Other Patient Characteristicsa 
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of patients within each age stratum among these groups (Table 
1). Males represented 61% of both the intervention and nonin-
tervention groups. A higher percentage of patients in the inter-
vention group were insulin users (31.0% vs. 25.8%, P = 0.004), 
while in the nonintervention group a higher percentage of 
patients were users of oral antidiabetic monotherapy (30.0% vs. 
25.4%, P = 0.016). Comorbidities, identified by relevant diagno-
sis codes documented during the 12-month period, were more 
frequent among nonintervention patients than intervention 
patients, with statistically significant differences observed for 
the prevalence of COPD (2.7% vs. 1.1%, respectively, P = 0.017) 
and CAD (16.5% vs. 11.9%, P = 0.002). The mean number of 
unique medications utilized per patient during the 12-month 
period was 12.2 for the intervention group compared with 12.9 
for the nonintervention group (P = 0.032). 
Patients in the intervention group were as likely as nonin-
tervention patients to have all of the recommended processes 
of care performed (40.1% vs. 38.9%, respectively, P = 0.543; 
Table 2). Among all processes of care, annual A1c testing was 
performed with the greatest frequency (92.3% of patients in 
the intervention group; 94.1% of nonparticipating patients, 
P = 0.064). Patients in the intervention group had lipid moni-
toring tests performed slightly less frequently than noninter-
vention patients (HDL-C testing: intervention group 85.7% 
vs. nonintervention group 89.7%, P = 0.001; LDL-C testing: 
intervention group 86.7% vs. nonintervention group 89.8%, 
P = 0.014). Rates of renal function testing (or use of a renal-
protective medication) were approximately the same between 
groups (intervention group 83.8% vs. nonintervention group 
83.3%, P = 0.726). The percentage of patients who received an 
eye examination during the 12-month period was the lowest of 
all measures, with 51.2% of intervention patients having docu-
mentation of an eye exam during the period, compared with 
48.0% of nonintervention patients (P = 0.114 between groups). 
Younger patients received all 5 of the recommended care 
processes less frequently than older patients (30.5%, 38.0%, 
and 47.0% for patients aged 18-48 years, 49-59 years, and 60 
years or older, respectively, P < 0.001). Females had all recom-
mended process of care performed more frequently than males 
(40.4% vs. 38.0%, P = 0.019), as did patients who were utilizing 
insulin (rate among patients with insulin use: 44.9% compared 
with 39.7% and 32.5% for patients using multiple oral therapy 
and oral monotherapy, respectively, P < 0.001). 
Table 3 presents the result of the multivariate logistic 
regression analysis including all covariates and intervention 
group status as a predictor of receiving the diabetes-related 
processes of care prior to adjustment using propensity scores. 
In this model, the OR for intervention group status adjusted 
for covariates was 1.06 (95% CI = 0.90-1.25), indicating that 
intervention patients were not more likely to have the diabetes-
related processes of care performed compared with the nonin-
tervention group. 
The likelihood of having the processes of care performed 
increased with age, as patients aged 49-59 years were 38% 
more likely to receive recommended care compared with 
patients aged 18-48 years (OR = 1.38, 95% CI = 1.23-1.53), 
while patients aged 60 years or older were approximately 
twice as likely to receive recommended care compared with 
the youngest age group (OR = 1.97, 95% CI = 1.75-2.21). 
Users of multiple oral antidiabetic therapies were 23% more 
likely to have the processes of care performed compared 
with users of oral antidiabetic monotherapy (OR = 1.23, 95% 
CI = 1.11-1.36), and patients who utilized insulin at any time 
during the measurement period were 59% more likely than 
users of oral monotherapy to receive these processes of care 
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Characteristic (n)
Beta  
Coefficient
Standard  
Error
Odds Ratio  
(95% CI)
Group 
Usual care (9,049) - - Reference
Intervention (649) 0.0588 0.0847  1.061 (0.898-1.252)
Age, years
18-48 (2,418) - - Reference
49-59 (4,239) 0.3181 0.0557  1.375 (1.233-1.533)
60 and older (3,041) 0.6759 0.0602  1.966 (1.747-2.212)
Gender
Female (3,804) - - Reference
Male (5,894) -0.0678 0.0446  0.934 (0.856-1.020)
Diabetes medication use
Oral monotherapy 
(2,878)
- - Reference
Multiple oral therapy 
(4,288)
0.2064 0.0525  1.229 (1.109-1.363)
Any insulin (2,532) 0.4621 0.0592  1.587 (1.414-1.783)
Comorbidity
Referenceb - - 1.0
Asthma (717) -0.1176 0.0836  0.889 (0.755-1.047)
CAD (1,568)  0.0393 0.0620  1.040 (0.921-1.174)
CHF (418)  0.0178 0.1086  0.982 (0.794-1.216)
COPD (251) -0.2410 0.1366  0.786 (0.601-1.027)
Mental health  
diagnosis (966)
-0.0818 0.0730  0.921 (0.799-1.063)
Number of unique medications utilized  
during the 12-month follow-up period
0-5 (1,254) - - Reference
6-10 (3,065) 0.3229 0.0759  1.381 (1.190-1.603)
11-20 (4,056) 0.6217 0.0750  1.862 (1.607-2.157)
21 or more (1,323) 0.7000 0.0930  2.014 (1.678-2.417)
aC-statistic = 0.60.
bReference group is the absence of the particular comorbidity.
CAD = coronary artery disease; CHF = congestive heart failure; CI = confidence 
interval; COPD = chronic obstructive pulmonary disease.
TABLE 3 Multivariate Logistic Regression 
Model:a Patient Covariates and 
Intervention Group Status as 
Predictors of Receiving All Diabetes-
Related Processes of Care 
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was not statistically significant ($7,475 vs. $8,577, respectively, 
P = 0.213). Differences in mean per-patient total costs incurred 
between the intervention and nonintervention groups were 
also not statistically significant ($10,614 vs. $11,431, respec-
tively, P = 0.666).
■■  Discussion
This study evaluated the results of a multifaceted approach 
implemented by a commercial health insurer designed to 
enhance diabetes management by providing patients with 
intensified oversight and counseling as provided by nurse case 
managers, coupled with reduced copayments for diabetes-
related medications as an incentive for participating in the 
intervention including care coordination and agreeing to 
receive recommended tests. The evaluation of this program 
focused upon determining rates of performance of 5 recom-
mended care processes and calculating costs of medical care 
and prescription drugs used during a 12-month period. 
As we were interested in evaluating the program during 
its initial phase, our approach was to compare results among 
(OR=1.59, 95% CI = 1.41-1.78). The likelihood of having the 
processes of care performed increased with each category of 
the number of unique medications used during the period, 
with patients utilizing 21 or more unique medications being 
most likely to receive the processes of care compared with 
patients utilizing 5 or fewer medications during the period 
(OR = 2.01, 95% CI = 1.68-2.42). Neither gender nor comorbid-
ity status was associated with differences in the likelihood of 
receiving the processes of care. 
The multivariate model incorporating the propensity-score 
weights included the intervention status variable and the pre-
dictors determined to be statistically significant in construct-
ing the propensity-score weighted model. These included age 
category, gender, the type of diabetes medication utilized, the 
comorbidities of asthma and COPD, and the number of unique 
medications used during the period. The propensity score-
adjusted model (Table 4) indicated that intervention group 
status was associated with a small yet statistically significant 
increase in the likelihood of receiving all of the recommended 
care processes during the 12-month time frame (adjusted 
OR = 1.09, 95% CI = 1.03-1.16).
We calculated mean per-patient all-cause health care costs 
accrued during the 12-month study period, categorized as 
medical care cost; prescription drug cost (for all drugs, not just 
diabetes drugs); and total costs, which represented the sum of 
medical and prescription drug costs (Figure 2). Prescription 
drug costs incurred by the payer over the 12-month period 
were greater for the intervention group than for nonparticipat-
ing patients ($3,139 vs. $2,854, respectively, P < 0.001). The 
average per-patient pharmacy copayment amounts for all drugs 
during the measurement period were $542 for intervention 
patients and $545 for nonintervention patients (P = 0.341). The 
average per-patient 12-month all-cause medical care costs were 
lower for intervention patients; however, this difference in cost 
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Beta 
Coefficient
Standard 
Error
Odds Ratio  
(95% CI)
Group
Nonintervention (n = 9,049)  -  - Reference
Intervention (n = 649) 0.0895 0.0293 1.094  
(1.033-1.158)
aVariables represented in the propensity score include age category, gender,  
asthma, COPD, the number of unique medications used, and the type of diabetes 
medication regimen utilized (oral monotherapy, multiple oral therapy, or any  
insulin use). C-statistic = 0.61.
CI = confidence interval; COPD = chronic obstructive pulmonary disease.
TABLE 4 Propensity-Score Adjusted Odds 
Ratio for Receiving All Diabetes-
Related Processes of Care for 
Program Participants (Intervention) 
Relative to Other Plan Members 
with Diabetes (Nonintervention)a
$12,000
$10,000
$8,000
$6,000
$4,000
$2,000
$0
Average 
Pharmacy 
Copayment
(P = 0.341)
Average Net 
Pharmacy 
Cost
(P < 0.001)
Average Net 
Medical 
 Cost
(P = 0.213)
Average  
Total Net 
Cost
(P = 0.666)
FIGURE 2 Average All-Cause Pharmacy, 
Medical, and Total Costs Per Patient 
for Intervention and Nonintervention 
Groups During the 12-Month Follow-
Up Measurement Period
Intervention Nonintervention
Allowed 
Pharmacy 
Charge ($)
Pharmacy 
Copayment 
($)
Pharmacy 
Net Plan 
Cost ($)a 
Medical  
Net Plan 
Cost ($)a
Total 
Pharmacy 
and  
Medical  
Net Plan 
Cost ($)a
Mean [SD]  
inter- 
vention
3,681 
[3,755]
542  
[554]
3,139 
[3,426]
7,475 
[17,601]
10,613 
[18,590]
Mean [SD]  
noninter-
vention
3,399 
[3,802]
545  
[457]
2,854 
[3,938]
8,577 
[22,972]
11,430 
[24,060]
aNet plan cost after subtraction of patient cost share.
SD = standard deviation.
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period, as measured by the prevalence of comorbidities and 
the number of medications utilized. This difference may have 
yielded closer oversight, more frequent provider contact, 
and perhaps more aggressive monitoring for nonintervention 
patients than for the relatively healthier patients in the inter-
vention group. Another proxy for disease burden is the number 
of unique medications utilized during the study time frame. 
The patients in the intervention group were less frequently 
categorized as using more than 10 medications, a finding that 
further suggests that intervention members were healthier and 
perhaps less intensely followed by care providers. 
Our analyses identified several factors that were associated 
with increased rates of performance of recommended care. 
Age was a most significant predictor, as patients aged 60 years 
or older were nearly twice as likely as patients aged 18 to 48 
years to receive these processes of care. Users of antidiabetic 
monotherapy and patients utilizing 5 or fewer different medi-
cations during the period were also less likely to have all of the 
processes of care performed. While the margin of improvement 
for the rates of performance of these processes care was great-
est among younger patients and patients utilizing antidiabetic 
monotherapy (compared with users of combination therapies 
or insulin), further research is necessary to determine how 
these subgroups specifically may respond to diabetes disease 
management programs. 
For comparison, we contrasted the rates observed in the 
present study with the NCQA HEDIS benchmarks described 
earlier.11 While we also included HDL-C monitoring in our 
evaluation, this measure is not included within HEDIS, yet 
is recommended by the American Diabetes Association. We 
assumed that HEDIS rates for HDL-C screening would be 
similar to HEDIS rates for LDL-C screening because both pro-
cedures are usually obtained with the same test. In contrasting 
our intervention sample’s rates with those published by the 
NCQA representing commercial insurers overall, we found 
intervention patients to have slightly higher rates for yearly 
A1c testing (92.3% vs. 89% for HEDIS), LDL-C testing (86.7% 
vs. 84.8% for HEDIS), and medical attention for nephropathy 
(83.8% vs. 82.4% for HEDIS). The percentage of members hav-
ing a yearly eye examination was slightly lower in our inter-
vention sample, with a rate of 51.2% versus 56.5% for HEDIS. 
Among nonintervention patients in our sample, rates were 
similar to those of intervention patients and, in fact, higher 
for lipid measurements. Thus, performance rates for these 
diabetes-related processes of care among both intervention and 
nonintervention patients were high, reflecting previous and/
or existing standard disease management programs provided 
to all members having diabetes. As such, the opportunity for 
improvement resulting from this diabetes incentive program 
may have been limited given the high baseline rates for most 
of these measures. 
An additional aim of this study was to determine whether 
intervention patients with usual care, by forming a comparison 
group comprising plan members with diabetes who did not 
participate in the intervention. This approach introduced the 
possibility of selection bias, as those agreeing to participate in 
the program may have differed in important ways from non-
participating members. For example, patients volunteering to 
participate in the program may have been more inclined than 
nonvolunteering patients to comply with blood testing for 
cholesterol monitoring and instructions for glycemic control. 
While the intervention patients were similar to patients in the 
comparison group with respect to age distribution and gender, 
they also utilized insulin more frequently and had a lesser 
prevalence of COPD (1.1% vs. 2.7%, respectively, P = 0.017) and 
CAD (11.9% vs. 16.5%, P = 0.002). These differences suggest 
that the intervention group in general had a lesser comorbid-
ity burden; yet, they may have had greater diabetes severity, 
as indicated by the larger percentage of patients with insulin 
dependence among intervention patients compared with non-
intervention patients (31.0% vs. 25.8%, respectively, P = 0.004). 
We attempted to control for the possibility of selection 
bias through the use of a propensity score-weighted model, as 
derived from a separate multivariate model that determined 
significant predictors of intervention group status. The results 
of this model were consistent with the findings of the bivari-
ate analyses, which found that intervention group members 
received these processes of care at a rate similar to that of 
patients who did not participate in the intervention (40.1% 
vs. 38.9%, respectively). In the multivariate logistic regression 
model including all covariates, intervention group status was 
not predictive of higher rates of performance of the recom-
mended care processes. When assessed using a multivariate 
model adjusted by propensity score, we found that members 
enrolled in the program were slightly more likely to have all 
of the recommended processes of care performed during the 
measurement period compared with members not enrolled in 
the program (OR = 1.09, 95% CI = 1.03-1.16). 
While this model indicated a small increase in the likeli-
hood of receiving all tests among intervention members, this 
finding was likely driven by the between-group difference in 
the rate of one particular test—eye examination rates (51.2% 
intervention vs. 48.0% nonintervention, P = 0.114)—as rates of 
LDL-C and HDL-C testing were slightly lower among interven-
tion patients. In sum, our results indicate that no meaningful 
difference existed between the intervention and noninterven-
tion groups with regard to performance of the processes of care 
measured. 
Our methodological approach did not permit randomiza-
tion of patients to the intervention; thus, our findings may have 
been influenced by between-group differences in the burden 
of disease and associated intensity of clinical management. 
Our analyses revealed that the intervention group patients 
were healthier than nonintervention patients during the study 
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example, a member could have been diagnosed with asthma 
on the last day of the 12-month period and would have been 
classified as having asthma for the entire study period.
Second, we evaluated all-cause costs but did not examine 
diabetes-related costs specifically. We sought to determine the 
overall cost impact associated with this disease management 
program, which included components potentially affecting 
expenditures for both diabetes and other health conditions, 
such as cardiovascular and renal disease. Additionally, we 
believed that reductions in diabetes-related costs would be 
more likely than reductions in all-cause costs to occur after the 
end of the 12-month measurement period. Nevertheless, there 
may have been a significant impact of this disease management 
program on diabetes-related costs in particular that was not 
identified. 
Third, we did not evaluate patient adherence to antidiabetic 
medications. While it was envisioned that copayment reduc-
tion might promote medication adherence, the copayment 
incentive was primarily designed to encourage patient inter-
est and involvement in the disease management program to 
enhance the quality of care overall, as assessed according to the 
diabetes-related care processes evaluated in this study. To par-
ticipate in the program and qualify for the copayment reduc-
tion, patients agreed to have an annual physical examination, 
have A1c and cholesterol testing performed at recommended 
intervals, and work with a care coordinator. Patients were not 
required to achieve a particular level of medication adherence. 
Thus, we focused our evaluation on the program components 
described in the patient pledge. 
Fourth, the all-or-none approach to the composite measure, 
which represented whether all of the processes of care were 
performed, could have missed overall better care. For example, 
receipt of 4 of 5 measures and receipt of 0 of 5 measures were 
both classified as failing to receive all recommended care. 
However, it was evident from the rates observed for each spe-
cific measure that the processes of care were performed with 
similar frequency for both the intervention and noninterven-
tion members. Another important limitation pertains to the 
lack of data available to identify the achievement of therapeutic 
goals. We determined only whether a test was performed; we 
were unable to determine the percentage of members who had 
their blood glucose and lipid levels reduced to recommended 
goals. Patients could have had all tests performed but still have 
values representing high risk of diabetic complications. 
A fifth limitation of this study is the nature of the admin-
istrative data source, which contained information about paid 
claims only. Any diagnosis, procedure, or medication dis-
pensing that occurred and was not recorded or that was paid 
out-of-pocket was not included in this study. Additionally, we 
assumed that dispensed medications were actually taken as 
prescribed by members, and in this analysis we did not assess 
adherence to dispensed medications. 
the diabetes incentive program was associated with differences 
in the costs of medical care and prescription drug utilization. 
While pharmacy costs were greater among the intervention 
group members, neither annual per-member medical costs 
nor total costs differed in statistical significance. The differ-
ence in average per-patient overall medical care cost during 
the period was $1,102, with the intervention patients incur-
ring less spending. This finding may reflect the difference in 
comorbidity prevalence between the intervention and nonin-
tervention groups yet also was influenced by outlier patients 
having extremely higher costs, as indicated by the difference 
in the range of costs between groups (intervention patients 
$43.9 to $199,694, SD = $17,601; nonintervention patients $0 to 
$514,394, SD = $22,972). The outlier values would not dramati-
cally influence the nonparametric statistical test applied, which 
explains the lack of statistical significance for the difference 
in medical care cost experienced between the groups. Further 
evaluation of this program over time will be informative in 
determining if cost reduction among intervention participants 
is achieved over the longer term. 
Intervention participants incurred higher expenditures for 
prescription drug utilization compared with nonintervention 
patients. This finding aligned with program expectations, given 
the expected increased cost borne by the plan for the reduced 
copayments for antidiabetic medications among intervention 
members. Yet further analyses revealed that dispensings for 
lower-cost generic medications were more frequent among 
nonintervention members. The mean (SD) generic dispensing 
ratio for all drugs (not just diabetes drugs) was 62.1% (22.4%) 
among intervention patients compared with 65.4% (23.0%) 
among nonintervention patients (P < 0.001, t-test, 2 sided). Due 
to the limitations of our observational study design, we were 
unable to determine the frequency of dispensing of generic 
medications among those patients who were offered the pro-
gram but declined to participate, which would enable a better 
understanding of the relative value of copayment reduction as 
perceived by patients using brand-name medication. Further 
research examining the effects of copayment reduction as a 
component of disease management in diabetes is warranted, 
particularly considering that the value of medication therapies 
is likely to be an increasingly important aspect of formulary 
designs. 
Limitations
Several limitations of this study should be recognized. First 
and most importantly, we were unable to make comparisons 
with prior periods to enable a pre-intervention versus post-
intervention analysis. The intervention may have provided 
greater gains in performance rates or greater reductions in cost 
from the previous year for those participating in the program, 
yet we were unable to measure this possible effect. Also, given 
the brief 12-month measurement time frame, we were unable 
to determine the temporal relationships between variables. For 
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APPEnDIx ICD-9-CM and CPT Codes Applied in Determining Process-of-Care Rates and Comorbiditiesa 
A1c (CPT)
83036, 83037
Asthma (ICD-9-CM)
493.XX
COPD (ICD-9-CM)
491.XX, 492.XX, 496
Coronary artery disease (ICD-9-CM)
410.XX - 414.XX
Diabetes mellitus (ICD-9-CM)
250.XX, 357.2, 362.0X, 366.41, 648.0X
Eye examinationb (CPT/ICD-9-CM)
CPT: 67028, 67030, 67031, 67036, 67038-67043, 67101, 67105, 67107, 67108, 67110, 67112, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 
67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92225, 92226, 92230, 92235, 92240, 92250, 92260 
ICD-09-CM: 14.1-14.5, 14.9, 95.02-95.04, 95.11, 95.12, 95.16
HDL-C (CPT)c
80061, 83700, 83701, 83704, 83718
Heart failure (ICD-9-CM) 
398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 428.XX 
LDL-C (CPT)
80061, 83700, 83701, 83704, 83721
Medical attention for nephropathyd (CPT/ICD-9-CM) 
81000-81003, 81005, 82042, 82043, 82044, 84156, 36145, 36800, 36810, 36815, 36818, 36819-36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 
50370, 50380, 90920, 90921, 90924, 90925, 90935, 90937, 90939, 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512 
ICD-9-CM: 250.4, 403, 404, 405.01, 405.11, 405.91, 580-588, 753.0, 753.1, 791.0, V42.0, V45.1, V56, 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95,  
54.98, 55.4-55.6
Mental health diagnoses (ICD-9-CM)e
293.XX, 294.XX, 295.XX, 296.XX, 297.XX, 298.XX, 299.XX
Polycystic ovary syndrome (ICD-9-CM)
256.4
aCode sets based upon HEDIS specifications except where noted.20
bCPT code list also includes codes for eye procedures as a proxy for dilated eye exam.
cHDL-C testing is not a HEDIS measure.
dCodes include a range of procedures that indicate provider attention to renal function per HEDIS specifications. 
eIncludes code sets for psychosis, schizophrenia, depression, and paranoia. 
A1c = hemoglobin A1c; COPD = chronic obstructive pulmonary disease; CPT = Current Procedural Terminology; HDL-C = high-density lipoprotein cholesterol; 
HEDIS = Healthcare Effectiveness Data and Information Set; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; LDL-C = low-
density lipoprotein cholesterol. 
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